These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 18379193)

  • 1. Plasma membrane phospholipid labeling to estimate tumor burden and kinetics.
    Dingli D; Lowe VJ
    Cancer Biol Ther; 2008 May; 7(5):748-9. PubMed ID: 18379193
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of radiolabeled choline and ethanolamine as probe for cancer detection.
    Mintz A; Wang L; Ponde DE
    Cancer Biol Ther; 2008 May; 7(5):742-7. PubMed ID: 18296919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Could choline PET play a role in malignancies other than prostate cancer?
    Nanni C; Rubello D; Fanti S
    Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):216-8. PubMed ID: 17899074
    [No Abstract]   [Full Text] [Related]  

  • 4. Imaging of a paraganglioma on C-11 choline PET/CT.
    Rahbar K; Fuchs M; Kemper S; Juergens KU; Weckesser M; Stegger L
    Clin Nucl Med; 2009 Feb; 34(2):119-21. PubMed ID: 19352271
    [No Abstract]   [Full Text] [Related]  

  • 5. Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate.
    Yoshimoto M; Waki A; Obata A; Furukawa T; Yonekura Y; Fujibayashi Y
    Nucl Med Biol; 2004 Oct; 31(7):859-65. PubMed ID: 15464387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis.
    Treglia G; Ceriani L; Sadeghi R; Giovacchini G; Giovanella L
    Clin Chem Lab Med; 2014 May; 52(5):725-33. PubMed ID: 24310773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer imaging with fluorine-18-labeled choline derivatives.
    Kwee SA; DeGrado TR; Talbot JN; Gutman F; Coel MN
    Semin Nucl Med; 2007 Nov; 37(6):420-8. PubMed ID: 17920349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of [(11)C]Choline ([(11)C]CHO) and [(18)F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model.
    Schwarzenböck SM; Schmeja P; Kurth J; Souvatzoglou M; Nawroth R; Treiber U; Kundt G; Berndt S; Graham K; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Dinkelborg L; Wester HJ; Krause BJ
    Mol Imaging Biol; 2016 Jun; 18(3):393-401. PubMed ID: 26483088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography.
    Miller PW; Long NJ; Vilar R; Gee AD
    Angew Chem Int Ed Engl; 2008; 47(47):8998-9033. PubMed ID: 18988199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond 18F-FDG: Characterization of PET/CT and PET/MR Scanners for a Comprehensive Set of Positron Emitters of Growing Application--18F, 11C, 89Zr, 124I, 68Ga, and 90Y.
    Soderlund AT; Chaal J; Tjio G; Totman JJ; Conti M; Townsend DW
    J Nucl Med; 2015 Aug; 56(8):1285-91. PubMed ID: 26135111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purification of carbon-11 PET radiotracers from unlabeled precursors by preparative HPLC and SPE.
    Zheng QH; Mock BH
    Biomed Chromatogr; 2005 Nov; 19(9):671-6. PubMed ID: 15803445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and Preclinical Evaluation of Three Novel Fluorine-18 Labeled Radiopharmaceuticals for P-Glycoprotein PET Imaging at the Blood-Brain Barrier.
    Savolainen H; Cantore M; Colabufo NA; Elsinga PH; Windhorst AD; Luurtsema G
    Mol Pharm; 2015 Jul; 12(7):2265-75. PubMed ID: 26043236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging of tumour hypoxia using PET and 18F-labelled tracers: biology meets technology.
    Grönroos T; Minn H
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1563-5. PubMed ID: 17598110
    [No Abstract]   [Full Text] [Related]  

  • 15. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
    Vallabhajosula S
    Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of PET imaging with radiolabelled choline (11C/18F-choline).
    Kirienko M; Sollini M; Lopci E; Versari A; Chiti A
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):83-94. PubMed ID: 25677590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current trends in using PET radiopharmaceuticals for diagnostics in oncology].
    Adam J; Kadeřávek J; Kužel F; Vašina J; Rehák Z
    Klin Onkol; 2014; 27 Suppl 1():S129-36. PubMed ID: 24945550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review.
    Treglia G; Giovannini E; Di Franco D; Calcagni ML; Rufini V; Picchio M; Giordano A
    Ann Nucl Med; 2012 Jul; 26(6):451-61. PubMed ID: 22566040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of PET/CT and current challenges in prostate cancer management.
    Lindholm P; Seppänen M; Minn H
    Nucl Med Commun; 2009 May; 30(5):325. PubMed ID: 19421025
    [No Abstract]   [Full Text] [Related]  

  • 20. Instant gratification must wait.
    Divgi C
    Eur J Nucl Med Mol Imaging; 2006 Sep; 33(9):979-80. PubMed ID: 16810529
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.